DermTech, Inc. has announced the launch of DermTech PLAplus, a test for the enhanced early detection of melanoma.

By combining RNA gene expression and DNA mutation analyses, PLAplus provides a non-invasive genomic test for enhanced early melanoma detection using an adhesive patch.

The new PLAplus test adds TERT (Telomerase Reverse Transcri­ptase) promoter DNA driver mutation analyses to the current RNA gene expression based Pigmented Lesion Assay (PLA), which includes LINC00518 and PRAME. TERT is individually associated with histopat­hologic features of aggressi­veness and poor survival in melanoma. The combined tests (LINC00518 and PRAME, plus TERT) elevate the sensitivity from 91%1 to 97% and maintain a negative predictive value of >99%, resulting in a less than 1% probability of missing melanoma 2,3.

Read more…

April 29, 2021